Minneapolis Heart Institute Foundation
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1982-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://mplsheart.org/
Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
Not yet recruiting
- Conditions
- Chronic Total OcclusionOcclusion
- Interventions
- Procedure: Chronic total occlusion percutaneous coronary intervention
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT05440084
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Phase 2
Recruiting
- Conditions
- Heart AttackEnlarged Heart
- Interventions
- Drug: SGLT-2 inhibitorsDrug: Placebo
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 81
- Registration Number
- NCT05305911
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
Recruiting
- Conditions
- Target Vessel Failure in Saphenous Vein GraftsPercutaneous Coronary Intervention
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 99
- Registration Number
- NCT05187351
- Locations
- ๐บ๐ธ
Henry Ford Health System, Detroit, Michigan, United States
๐บ๐ธMinneapolis Heart Institute Foundation, MInneapolis, Minnesota, United States
Progress Bifurcation Global Registry
Recruiting
- Conditions
- Coronary Bifurcation LesionsCoronary Artery Disease
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 4000
- Registration Number
- NCT05100992
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Progress Complication
Recruiting
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 4000
- Registration Number
- NCT05100940
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
Phase 4
- Conditions
- Contrast Media ReactionCoronary Artery Disease
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 62
- Registration Number
- NCT05065073
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Racial and Economic Disparities and Unmet Needs in Patients With Severe Aortic Valvular Disease
- Conditions
- Disparities in Treatment of Aortic Valve StenosisAortic Valve Stenosis
- Interventions
- Other: Patient QuestionnaireOther: Provider Questionnaire
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT04525937
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Not Applicable
- Conditions
- Vascular Access ComplicationPatient Satisfaction
- Interventions
- Procedure: Radial AccessProcedure: State-of-the-art femoral access with 18 gauge needleProcedure: State-of-the-art femoral access with 21 gauge needle
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 3266
- Registration Number
- NCT04077762
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial
Phase 4
- Conditions
- Cardiovascular DiseasesAdverse EffectCardiovascular Risk Factor
- Interventions
- Drug: Rosuvastatin 20mgOther: Placebo
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 25
- Registration Number
- NCT03889314
- Locations
- ๐บ๐ธ
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Phase 4
Terminated
- Conditions
- Saphenous Vein Graft Atherosclerosis
- Interventions
- Drug: Matching Placebo subcutaneous injectionDrug: Alirocumab 150 MG/ML subcutaneous injection
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Minneapolis Heart Institute Foundation
- Target Recruit Count
- 46
- Registration Number
- NCT03542110
- Locations
- ๐บ๐ธ
San Francisco VA Medical Center, San Francisco, California, United States
๐บ๐ธAtlanta VA Medical Center, Atlanta, Georgia, United States
๐บ๐ธMinneapolis Heart Institute/ Abbott North Western Hospital-Allina Health, Minneapolis, Minnesota, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath